{"id":1452,"date":"2016-11-22T05:39:03","date_gmt":"2016-11-22T05:39:03","guid":{"rendered":"http:\/\/www.getbetterbodysystem.com\/fat-loss-tips\/glaxosmithkline-seeks-u-s-approval-for-triple-lung-drug\/"},"modified":"2016-11-22T05:39:03","modified_gmt":"2016-11-22T05:39:03","slug":"glaxosmithkline-seeks-u-s-approval-for-triple-lung-drug","status":"publish","type":"post","link":"http:\/\/www.getbetterbodysystem.com\/fat-loss-tips\/glaxosmithkline-seeks-u-s-approval-for-triple-lung-drug\/","title":{"rendered":"GlaxoSmithKline seeks U.S. approval for triple lung drug"},"content":{"rendered":"
LONDON (Reuters) – GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light.<\/p>\n